Partner HGSI Files Benlysta For US Approval: GSK
First potentially new treatment in decades for the hard-to-treat autoimmune disease lupus might be on the shelves soon as GlaxoSmithKline Plc (GSK) on Thursday said partner Human Genome Sciences Inc. (HGSI) has applied for U. S. regulatory approval for their jointly-developed drug Benlysta.
As of now no where in the world Benlysta, or belimumab, is approved or licensed but there are high hopes for the treatment by the U. K. drug maker and its Rockville, Md.-based partner. An application earlier this month was submitted to the FDA for a Biologics License to Europe's drug regulator for marketing approval there.
H. Thomas Watkins, President and Chief Executive Officer of Human Genome Sciences, said, "Based on the results of our pivotal Phase 3 studies, we believe Benlysta has the potential to become the first new approved drug for systemic lupus in more than 50 years."
The drug can be expected in the market late this year or in early 2011.
New Zealand News
- Tesla Model Y Performance becomes little bit more expensive to order in China
- Porsche’s recently unveiled Mission R Concept previews electric race cars of future
- Chinese manufacturer GAC’s Aion V e-SUV can charge 0-80% in just 8 minutes
- Oshidori International exits Japanese casino race, citing serious ethical irregularities
- CATL and LG Energy account for nearly 54% of global xEV battery market: SNE Research
- Micro Mobility shows off production version of Microlino 2.0 and 3-wheeled e-scooter
- Chinese electric motorcycle maker Evoke Motorcycles to set up shops in Spain
- TenneT adds more electric BMWs to study use of EVs to support power grids
- Italy’s ASPI announces plans to install cross-country ultra-fast EV charging network
- EV ownership costs significantly lower than conventional models: French Study